Crescendo Biologics, a life sciences spin-out company of the Babraham Institute, has received £17.5m ($28.9m) in a series A supported by new and existing backers, including the corporate venturing arm of Astellas Pharma. The round was led by Imperial Innovations, the tech transfer unit of Imperial College London, marking the latest in a string of…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
